PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial — PORTICO

Portopulmonary Hypertension Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension

Status Completed

Clinical Trial Summary

24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02382016
Study type	Interventional
Source	Actelion
Contact
Status	Completed
Phase	Phase 4
Start date	June 23, 2015
Completion date	October 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03309592` - Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension	Phase 4
Completed	`NCT01028651` - A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension	N/A
Terminated	`NCT01517854` - Revatio Portal-Pulmonary Arterial Hypertension Trial	Phase 2
Completed	`NCT01224210` - Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial	Phase 3
Withdrawn	`NCT01733095` - Ambrisentan for Treatment of Portopulmonary Hypertension	Phase 1/Phase 2